In this regard, several years ago, we tested the efficacy of a combination treatment with immunotherapy (recombinant IL-2), anti-inflammatory agent (medroxyprogesterone acetate), and antioxidants in patients with advanced cancer [99,100]. This evidence concerns the gene IL2 and cancer.